In a breakthrough for cancer treatment in India, Apollo Cancer Centres (ACCs) has unveiled the country's first 'Made in India' CAR-T cell therapy programme. This announcement comes hot on the heels of ACCs' successful completion of the CAR-T cell therapy programme, making it the first private hospital group in India to achieve this milestone.

CAR-T cell therapy, often hailed as a 'living drug', involves harnessing a patient's T-cells, genetically modifying them, and reintroducing them into the body to target cancer cells. The introduction of the 'Made in India' CAR-T cell programme marks a significant leap forward in the fight against B-cell lymphomas and B-acute lymphoblastic leukaemia, especially for patients aged 15 years and above.

Dr. Anupam Chakrapani, Senior Consultant - Haematology & BMT Specialist at ACC, Calcutta, expressed his excitement, stating, "The successful treatment of three patients using CAR-T Cell therapy signifies a major advancement in our battle against these challenging conditions. This therapy offers new hope and possibilities for patients."

Echoing Dr. Chakrapani's sentiments, Dr. Rajat Bhattacharyya, Senior Consultant - Pediatric Haematology, ACC, Calcutta, emphasized the transformative potential of CAR-T cell therapy in cancer treatment in India. He said, "The launch of the 'Made in India' CAR-T cell programme represents a pivotal moment in cancer care, offering a ray of hope for patients grappling with B-cell malignancies."

Mr. Rana Dasgupta, CEO Eastern Region, ACC Calcutta, Apollo Hospitals Enterprises Limited, underscored ACC's commitment to pioneering healthcare solutions. He remarked, "With the introduction of NexCAR19, our indigenously built CAR-T treatment, we are rewriting the possibilities of cancer treatment in India. This achievement reaffirms our dedication to providing accessible and effective healthcare solutions."

Apollo Cancer Centres has long been at the forefront of cancer care in India, boasting a network of over 325 oncologists delivering world-class treatment. The launch of the 'Made in India' CAR-T cell therapy programme marks yet another milestone in ACC's journey towards revolutionizing cancer treatment in the country.